Abivax receives a "Strong Buy" rating, driven by positive phase 3 ABTECT induction data for obefazimod in moderate-to-severe ...
Streamlined pharmacologic recommendations challenge the stepwise approach for moderately to severely active disease.
TipRanks on MSN
SinoMab’s SM17 IND application for IBD accepted by NMPA
An update from SinoMab Bioscience Ltd. ( ($HK:3681) ) is now available. SinoMab BioScience Limited announced that its Investigational New Drug ...
Wellbeing Whisper on MSN
Hidden dangers of GLP‑1 weight‑loss drugs you need to know
What if the race to get thin was quietly putting health at risk? That question is becoming harder to ignore as glucagon‑like ...
New approaches hurdle biological barriers to attack recalcitrant targets to tackle difficult-to-treat and recurrent cancers.
Crofelemer can potentially extend lives of MVID patients – infants and children who face the lethal natural history of the disease Parenteral support reduction of up to 37% is groundbreaking; No ...
The Food and Drug Administration (FDA) has issued a statement, published electronically in the New England Journal of Medicine (NEJM) on November 12, 2025, proposing a new process for obtaining ...
Copyright 2025 The Associated Press. All Rights Reserved. Copyright 2025 The Associated Press. All Rights Reserved. The president says that he “probably would talk ...
Identifying the mechanisms of action driving a drug’s anti-cancer efficacy is critical for identifying optimal biomarkers, indications, and combinations for clinical success. Yet, systematically ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback